Elevated heart rate and cardiovascular outcomes in patients with coronary artery disease: Clinical evidence and pathophysiological mechanisms


      There is an established body of evidence from epidemiological studies which indicates that an elevated resting heart rate is independently associated with atherosclerosis and increased cardiovascular morbidity and mortality, in both the general population and in patients with established cardiovascular disease. Clinical trial data suggest that in patients with coronary artery disease, an elevated heart rate identifies those at increased risk of adverse cardiovascular outcomes, and that lowering of heart rate may reduce major cardiovascular events in patients with an elevated heart rate and symptom-limiting angina. These results suggest that an increased heart rate may have an adverse impact on the atherosclerotic process and increase the risk of a cardiovascular event in patients with coronary artery disease. The precise pathophysiological mechanisms that link heart rate and cardiovascular outcomes have yet to be defined. Possibilities may include indirect mechanisms related to autonomic dysregulation and those due to an increase in heart rate per se, which can increase the ischaemic burden and exert local haemodynamic forces that can adversely impact on the endothelium and arterial wall. For these reasons, heart rate should be considered as a therapeutic target in the treatment of patients with coronary artery disease.


      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'


      Subscribe to Atherosclerosis
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect


        • Aboyans V.
        • Criqui M.H.
        Can we improve cardiovascular risk prediction beyond risk equations in the physician's office?.
        J Clin Epidemiol. 2006; 59: 547-558
        • Palatini P.
        Heart rate as an independent risk factor for cardiovascular disease: current evidence and basic mechanisms.
        Drugs. 2007; 67: 3-13
        • Fox K.
        • Ford I.
        • Steg P.G.
        • et al.
        Heart rate as a prognostic risk factor in patients with coronary artery disease and left ventricular systolic dysfunction (BEAUTIFUL): a subgroup analysis of a randomised controlled trial.
        Lancet. 2008; 372: 817-821
        • Perski A.
        • Olsson G.
        • Landou C.
        • et al.
        Minimum heart rate and coronary atherosclerosis: independent relations to global severity and rate of progression of angiographic lesions in men with myocardial infarction at a young age.
        Am Heart J. 1992; 123: 609-616
        • Huikuri H.V.
        • Jokinen V.
        • Syvänne M.
        • et al.
        Heart rate variability and progression of coronary atherosclerosis.
        Arterioscler Thromb Vasc Biol. 1999; 19: 1979-1985
        • Heidland U.E.
        • Strauer B.E.
        Left ventricular muscle mass and elevated heart rate are associated with coronary plaque disruption.
        Circulation. 2001; 104: 1477-1482
        • Diaz A.
        • Bourassa M.G.
        • Guertin M.C.
        • Tardif J.C.
        Long-term prognostic value of resting heart rate in patients with suspected or proven coronary artery disease.
        Eur Heart J. 2005; 26: 967-974
        • Hjalmarson A.
        • Gilpin E.A.
        • Kjekshus J.
        • et al.
        Influence of heart rate on mortality after acute myocardial infarction.
        Am J Cardiol. 1990; 65: 547-553
        • Disegni E.
        • Goldbourt U.
        • Reicher-Reiss H.
        • et al.
        The predictive value of admission heart rate on mortality in patients with acute myocardial infarction. SPRINT Study Group. secondary prevention reinfarction israeli nifedipine trial.
        J Clin Epidemiol. 1995; 48: 1197-1205
        • Zuanetti G.
        • Hernández-Bernal F.
        • Rossi A.
        • et al.
        Relevance of heart rate as a prognostic factor in myocardial infarction: the GISSI experience.
        Eur Heart J. 1999; 1: H52-H57
        • Marchioli R.
        • Avanzini F.
        • Barzi F.
        • et al.
        Assessment of absolute risk of death after myocardial infarction by use of multiple-risk-factor assessment equations: GISSI-Prevenzione mortality risk chart.
        Eur Heart J. 2001; 22: 2085-2103
        • Hjalmarson A.
        Heart rate: an independent risk factor in cardiovascular disease.
        Eur Heart J. 2007; 9: F3-F7
        • Kjekshus J.K.
        Importance of heart rate in determining beta-blocker efficacy in acute and long-term acute myocardial infarction intervention trials.
        Am J Cardiol. 1986; 57: 43F-49F
        • Lechat P.
        • Hulot J.S.
        • Escolano S.
        • et al.
        Heart rate and cardiac rhythm relationships with bisoprolol benefit in chronic heart failure in CIBIS II Trial.
        Circulation. 2001; 103: 1428-1433
        • Gullestad L.
        • Wikstrand J.
        • Deedwania P.
        • et al.
        What resting heart rate should one aim for when treating patients with heart failure with a beta-blocker? Experiences from the metoprolol controlled release/extended release randomised intervention trial in chronic heart failure (MERIT-HF).
        J Am Coll Cardiol. 2005; 45: 252-259
        • Flannery G.
        • Gehrig-Mills R.
        • Billah B.
        • Krum H.
        Analysis of randomised controlled trials on the effect of magnitude of heart rate reduction on clinical outcomes in patients with systolic chronic heart failure receiving beta-blockers.
        Am J Cardiol. 2008; 101: 865-869
        • Messerli F.H.
        • Oparil S.
        • Feng Z.
        Comparison of efficacy and side effects of combination therapy of angiotensin-converting enzyme inhibitor (benazepril) with calcium antagonist (either nifedipine or amlodipine) versus high-dose calcium antagonist monotherapy for systemic hypertension.
        Am J Cardiol. 2000; 86: 1182-1187
        • The Multicenter Diltiazem Postinfarction Trial Research Group
        The effect of diltiazem on mortality and reinfarction after myocardial infarction.
        N Engl J Med. 1988; 319: 385-392
        • Hedblad B.
        • Wikstrand J.
        • Janzon L.
        • Wedel H.
        • Berglund G.
        Low-dose metoprolol CR/XL and fluvastatin slow progression of carotid intima-media thickness: Main results from the Beta-Blocker Cholesterol-Lowering Asymptomatic Plaque Study (BCAPS).
        Circulation. 2001; 103: 1721-1726
        • Sipahi I.
        • Tuzcu E.M.
        • Wolski K.E.
        • et al.
        Beta-blockers and progression of coronary atherosclerosis: pooled analysis of 4 intravascular ultrasonography trials.
        Ann Intern Med. 2007; 147: 10-18
        • Nissen S.E.
        • Tuzcu E.M.
        • Schoenhagen P.
        • et al.
        Effect of intensive compared with moderate lipid-lowering therapy on progression of coronary atherosclerosis: a randomised controlled trial.
        JAMA. 2004; 291: 1071-1080
        • Shattock M.
        • Camm A.J.
        Pure heart rate reduction: the If channels from discovery to therapeutic target.
        Br J Cardiol. 2006; 13: 27-35
        • Tardif J.C.
        • Ford I.
        • Tendera M.
        • Bourassa M.G.
        • Fox K.
        • INITIATIVE Investigators
        Efficacy of ivabradine, a new selective I(f) inhibitor, compared with atenolol in patients with chronic stable angina.
        Eur Heart J. 2005; 26: 2529-2536
        • Ruzyllo W.
        • Tendera M.
        • Ford I.
        • Fox K.M.
        Anti-anginal efficacy and safety of ivabradine compared with amlodipine in patients with stable effort angina pectoris: a 3-month randomised, double-blind, multicentre, noninferiority trial.
        Drugs. 2007; 67: 393-405
        • Mulder P.
        • Barbier S.
        • Chagraoui A.
        • et al.
        Long-term heart rate reduction induced by the selective I(f) current inhibitor ivabradine improves left ventricular function and intrinsic myocardial structure in congestive heart failure.
        Circulation. 2004; 109: 1674-1679
        • Fox K.
        • Ford I.
        • Steg P.G.
        • Tendera M.
        • Ferrari R.
        • BEAUTIFUL Investigators
        Ivabradine for patients with stable coronary artery disease and left ventricular systolic dysfunction (BEAUTIFUL): a randomised, double-blind, placebo-controlled trial.
        Lancet. 2008; 372: 807-816
        • Fox K.
        • Ford I.
        • Steg P.G.
        • et al.
        Relationship between ivabradine treatment and cardiovascular outcomes in patients with stable coronary artery disease and left ventricular systolic dysfunction with limiting angina: a subgroup analysis of the randomised, controlled BEAUTIFUL trial.
        Eur Heart J. 2009; 30: 2337-2345
        • Beere P.A.
        • Glagov S.
        • Zarins C.K.
        Retarding effect of lowered heart rate on coronary atherosclerosis.
        Science. 1984; 226: 180-182
        • Kaplan J.R.
        • Manuck S.B.
        • Adams M.R.
        • Weingand K.W.
        • Clarkson T.B.
        Inhibition of coronary atherosclerosis by propranolol in behaviorally predisposed monkeys fed an atherogenic diet.
        Circulation. 1987; 76: 1364-1372
        • Albaladejo P.
        • Carusi A.
        • Apartian A.
        • et al.
        Effect of chronic heart rate reduction with ivabradine on carotid and aortic structure and function in normotensive and hypertensive rats.
        J Vasc Res. 2003; 40: 320-328
        • Custodis F.
        • Baumhäkel M.
        • Schlimmer N.
        • et al.
        Heart rate reduction by ivabradine reduces oxidative stress, improves endothelial function, and prevents atherosclerosis in apolipoprotein E-deficient mice.
        Circulation. 2008; 117: 2377-2387
        • Drouin A.
        • Gendron M.E.
        • Thorin E.
        • et al.
        Chronic heart rate reduction by ivabradine prevents endothelial dysfunction in dyslipidaemic mice.
        Br J Pharmacol. 2008; 154: 749-757
        • Task Force of the European Society of Cardiology the North American Society of Pacing Electrophysiology
        Heart rate variability: standards of measurement, physiological interpretation and clinical use.
        Circulation. 1996; 93: 1043-1065
        • Malik M.
        • Camm A.J.
        Heart rate variability: from fact to fancies.
        J Am Coll Cardiol. 1993; 22: 566-568
        • Bigger Jr., J.T.
        • Fleiss J.L.
        • Steinman R.C.
        • et al.
        Frequency-domain measures of heart period variability and mortality after myocardial infarction.
        Circulation. 1992; 85: 164-171
        • Huikuri H.V.
        • Mäkikallio T.H.
        Heart rate variability in ischemic heart disease.
        Auton Neurosci. 2001; 90: 95-101
        • Rich M.W.
        • Saini J.S.
        • Kleiger R.E.
        • et al.
        Correlation of heart rate variability with clinical and angiographic variables and late mortality after coronary angiography.
        Am J Cardiol. 1988; 62: 714-717
        • Airaksinen K.E.
        • Ikäheimo M.J.
        • Linnaluoto M.K.
        • Niemelä M.
        • Takkunen J.T.
        Impaired vagal heart rate control in coronary artery disease.
        Br Heart J. 1987; 58: 592-597
        • Hayano J.
        • Sakakibara Y.
        • Yamada M.
        • et al.
        Decreased magnitude of heart rate spectral components in coronary artery disease. Its relation to angiographic severity.
        Circulation. 1990; 81: 1217-1224
        • Wennerblom B.
        • Lurje L.
        • Tygesen H.
        • Vahisalo R.
        • Hjalmarson A.
        Patients with uncomplicated coronary artery disease have reduced heart rate variability mainly affecting vagal tone.
        Heart. 2000; 83: 290-294
        • Forslund L.
        • Björkander I.
        • Ericson M.
        • et al.
        Prognostic implications of autonomic function assessed by analyses of catecholamines and heart rate variability in stable angina pectoris.
        Heart. 2002; 87: 415-422
        • Bjorkander I.
        • Forslund L.
        • Kahan T.
        • et al.
        Differential index: a simple time-domain heart rate variability analysis with prognostic implications in stable angina pectoris.
        Cardiology. 2008; 111: 126-133
        • Chattipakorn N.
        • Incharoen T.
        • Kanlop N.
        • Chattipakorn S.
        Heart rate variability in myocardial infarction and heart failure.
        Int J Cardiol. 2007; 120: 289-296
        • Lanza G.A.
        • Guido V.
        • Galeazzi M.M.
        • et al.
        Prognostic role of heart rate variability in patients with a recent acute myocardial infarction.
        Am J Cardiol. 1998; 82: 1323-1328
        • Buccelletti E.
        • Gilardi E.
        • Scaini E.
        • et al.
        Heart rate variability and myocardial infarction: systematic literature review and metanalysis.
        Eur Rev Med Pharmacol Sci. 2009; 13: 299-307
        • Haensel A.
        • Mills P.J.
        • Nelesen R.A.
        • Ziegler M.G.
        • Dimsdale J.E.
        The relationship between heart rate variability and inflammatory markers in cardiovascular diseases.
        Psychoneuroendocrinology. 2008; 33: 1305-1312
        • Sajadieh A.
        • Nielsen O.W.
        • Rasmussen V.
        • et al.
        Increased heart rate and reduced heart rate variability are associated with subclinical inflammation in middle-aged and elderly subjects with no apparent heart disease.
        Eur Heart J. 2004; 25: 363-370
        • Sajadieh A.
        • Nielsen O.W.
        • Rasmussen V.
        • Hein H.O.
        • Hansen J.F.
        C-reactive protein, heart rate variability and prognosis in community subjects with no apparent heart disease.
        J Intern Med. 2006; 260: 377-387
        • Rogowski O.
        • Shapira I.
        • Shirom A.
        • et al.
        Heart rate and microinflammation in men: a relevant atherothrombotic link.
        Heart. 2007; 93: 940-944
        • Spertus J.A.
        • Jones P.
        • McDonell M.
        • Fan V.
        • Fihn S.D.
        Health status predicts long-term outcome in outpatients with coronary disease.
        Circulation. 2002; 106: 43-49
        • Mozaffarian D.
        • Bryson C.L.
        • Spertus J.A.
        • McDonell M.B.
        • Fihn S.D.
        Anginal symptoms consistently predict total mortality among outpatients with coronary artery disease.
        Am Heart J. 2003; 146: 1015-1022
        • Cohn P.F.
        Total ischemic burden: definition, mechanisms, and therapeutic implications.
        Am J Med. 1986; 81: 2-6
        • Deedwania P.C.
        • Carbajal E.V.
        Silent ischemia during daily life is an independent predictor of mortality in stable angina.
        Circulation. 1990; 81: 748-756
        • Yeung A.C.
        • Barry J.
        • Orav J.
        • et al.
        Effects of asymptomatic ischaemia on long-term prognosis in chronic stable coronary disease.
        Circulation. 1991; 83: 1598-1604
        • Dargie H.J.
        • Ford I.
        • Fox K.M.
        • Total Ichaemic Burden European Trial (TIBET)
        Effects of ischaemia and treatment with atenolol, nifedipine SR and their combination on outcome in patients with chronic stable angina. The TIBET Study Group.
        Eur Heart J. 1996; 17: 104-112
        • Gehi A.K.
        • Ali S.
        • Na B.
        • Schiller N.B.
        • Whooley M.A.
        Inducible ischemia and the risk of recurrent cardiovascular events in outpatients with stable coronary heart disease: the heart and soul study.
        Arch Intern Med. 2008; 168: 1423-1428
        • Tanaka N.
        • Nozawa T.
        • Yasumura Y.
        • et al.
        Heart rate-proportional oxygen consumption for constant cardiac work in dog heart.
        Jpn J Physiol. 1990; 40: 503-521
        • Rocco M.B.
        • Barry J.
        • Campbell S.
        • et al.
        Circadian variation of transient myocardial ischemia in patients with coronary artery disease.
        Circulation. 1987; 75: 395-400
        • Deanfield J.E.
        • Maseri A.
        • Selwyn A.P.
        • et al.
        Myocardial ischaemia during daily life in patients with stable angina: its relation to symptoms and heart rate changes.
        Lancet. 1983; 2: 753-758
        • Andrews T.C.
        • Fenton T.
        • Toyosaki N.
        • et al.
        Subsets of ambulatory myocardial ischemia based on heart rate activity. Circadian distribution and response to anti-ischemic medication. The Angina and Silent Ischemia Study Group (ASIS).
        Circulation. 1993; 88: 92-100
        • Pratt C.M.
        • McMahon R.P.
        • Goldstein S.
        • et al.
        Comparison of subgroups assigned to medical regimens used to suppress cardiac ischemia (the Asymptomatic Cardiac Ischemia Pilot [ACIP] Study).
        Am J Cardiol. 1996; 77: 1302-1309
        • Nakagomi A.
        • Celermajer D.S.
        • Lumley T.
        • Freedman S.B.
        Angiographic severity of coronary narrowing is a surrogate marker for the extent of coronary atherosclerosis.
        Am J Cardiol. 1996; 78: 516-519
        • Kloner R.A.
        • Kirshenbaum J.
        • Lange R.
        • Antman E.M.
        • Braunwald E.
        Experimental and clinical observations on the efficacy of esmolol in myocardial ischemia.
        Am J Cardiol. 1985; 56: 40F-48F
        • Matsuzaki M.
        • Guth B.
        • Tajimi T.
        • Kemper W.S.
        • Ross Jr., J.
        Effect of the combination of diltiazem and atenolol on exercise-induced regional myocardial ischemia in conscious dogs.
        Circulation. 1985; 72: 233-243
        • Colin P.
        • Ghaleh B.
        • Monnet X.
        • et al.
        Contributions of heart rate and contractility to myocardial oxygen balance during exercise.
        Am J Physiol Heart Circ Physiol. 2003; 284: H676-H682
        • Colin P.
        • Ghaleh B.
        • Monnet X.
        • Hittinger L.
        • Berdeaux A.
        Effect of graded heart rate reduction with ivabradine on myocardial oxygen consumption and diastolic time in exercising dogs.
        J Pharmacol Exp Ther. 2004; 308: 236-240
        • Feringa H.H.
        • Bax J.J.
        • Boersma E.
        • et al.
        High-dose beta-blockers and tight heart rate control reduce myocardial ischemia and troponin T release in vascular surgery patients.
        Circulation. 2006; 114: I344-I349
        • von Arnim T.
        Prognostic significance of transient ischemic episodes: response to treatment shows improved prognosis. Results of the Total Ischemic Burden Bisoprolol Study (TIBBs) follow-up.
        J Am Coll Cardiol. 1996; 28: 20-24
        • Stone P.H.
        • Gibson R.S.
        • Glasser S.P.
        • et al.
        Comparison of propranolol, diltiazem, and nifedipine in the treatment of ambulatory ischemia in patients with stable angina. Differential effects on ambulatory ischemia, exercise performance, and anginal symptoms. The ASIS Study Group.
        Circulation. 1990; 82: 1962-1972
        • Borer J.S.
        • Fox K.
        • Jaillon P.
        • Lerebours G.
        • Ivabradine Investigators Group
        Anti-anginal and anti-ischemic effects of ivabradine, an I(f) inhibitor, in stable angina: a randomised, double-blind, multicentered, placebo-controlled trial.
        Circulation. 2003; 107: 817-823
        • Tardif J.C.
        • Ponikowski P.
        • Kahan T.
        • ASSOCIATE Study Investigators
        Efficacy of the I(f) current inhibitor ivabradine in patients with chronic stable angina receiving beta-blocker therapy: a 4-month, randomised, placebo-controlled trial.
        Eur Heart J. 2009; 30: 540-548
        • Pepine C.J.
        • Cohn P.F.
        • Deedwania P.C.
        • et al.
        Effects of treatment on outcome in mildly symptomatic patients with ischemia during daily life. The Atenolol Silent Ischemia Study (ASIST).
        Circulation. 1994; 90: 762-768
        • Davies R.F.
        • Goldberg A.D.
        • Forman S.
        • et al.
        Asymptomatic Cardiac Ischemia Pilot (ACIP) study two-year follow-up: outcomes of patients randomised to initial strategies of medical therapy versus revascularisation.
        Circulation. 1997; 95: 2037-2043
        • Boden W.E.
        • O’Rourke R.A.
        • Teo K.K.
        • et al.
        Optimal medical therapy with or without PCI for stable coronary disease.
        N Engl J Med. 2007; 356: 1503-1516
        • Chatzizisis Y.S.
        • Coskun A.U.
        • Jonas M.
        • et al.
        Role of endothelial shear stress in the natural history of coronary atherosclerosis and vascular remodeling: molecular, cellular, and vascular behavior.
        J Am Coll Cardiol. 2007; 49: 2379-2393
        • Malek A.M.
        • Alper S.L.
        • Izumo S.
        Hemodynamic shear stress and its role in atherosclerosis.
        JAMA. 1999; 282: 2035-2042
        • Soulis J.V.
        • Giannoglou G.D.
        • Chatzizisis Y.S.
        • et al.
        Spatial and phasic oscillation of non-Newtonian wall shear stress in human left coronary artery bifurcation: an insight to atherogenesis.
        Coron Artery Dis. 2006; 17: 351-358
        • Traub O.
        • Berk B.C.
        Laminar shear stress: mechanisms by which endothelial cells transduce an atheroprotective force.
        Arterioscler Thromb Vasc Biol. 1998; 18: 677-685
        • Tzima E.
        • Irani-Tehrani M.
        • Kiosses W.B.
        • et al.
        A mechanosensory complex that mediates the endothelial cell response to fluid shear stress.
        Nature. 2005; 437: 426-431
        • Li Y.S.
        • Haga J.H.
        • Chien S.
        Molecular basis of the effects of shear stress on vascular endothelial cells.
        J Biomech. 2005; 38: 1949-1971
        • Gimbrone Jr., M.A.
        • Topper J.N.
        • Nagel T.
        • Anderson K.R.
        • Garcia-Cardena G.
        Endothelial dysfunction, hemodynamic forces, and atherogenesis.
        Ann N Y Acad Sci. 2000; 902: 230-239
        • Resnick N.
        • Yahav H.
        • Shay-Salit A.
        • et al.
        Fluid shear stress and the vascular endothelium: for better and for worse.
        Prog Biophys Mol Biol. 2003; 81: 177-199
        • Giannoglou G.D.
        • Chatzizisis Y.S.
        • Zamboulis C.
        • et al.
        Elevated heart rate and atherosclerosis: an overview of the pathogenetic mechanisms.
        Int J Cardiol. 2008; 126: 302-312
        • Kozuma K.
        • Costa M.A.
        • Sabaté M.
        • et al.
        Relationship between tensile stress and plaque growth after balloon angioplasty treated with and without intracoronary beta-brachytherapy.
        Eur Heart J. 2000; 21: 2063-2070
        • Lee R.T.
        • Schoen F.J.
        • Loree H.M.
        • Lark M.W.
        • Libby P.
        Circumferential stress and matrix metalloproteinase 1 in human coronary atherosclerosis. Implications for plaque rupture.
        Arterioscler Thromb Vasc Biol. 1996; 16: 1070-1073
        • Thubrikar M.J.
        • Robicsek F.
        Pressure-induced arterial wall stress and atherosclerosis.
        Ann Thorac Surg. 1995; 59: 1594-1603
        • Palatini P.
        • Benetos A.
        • Grassi G.
        • et al.
        Identification and management of the hypertensive patient with elevated heart rate: statement of a European society of hypertension consensus meeting.
        J Hypertens. 2006; 24: 603-610
        • Bassiouny H.S.
        • Zarins C.K.
        • Kadowaki M.H.
        • Glagov S.
        Hemodynamic stress and experimental aortoiliac atherosclerosis.
        J Vasc Surg. 1994; 19: 426-434
        • Mangoni A.A.
        • Mircoli L.
        • Giannattasio C.
        • Ferrari A.U.
        • Mancia G.
        Heart rate-dependence of arterial distensibility in vivo.
        J Hypertens. 1996; 14: 897-901
        • Mircoli L.
        • Mangoni A.A.
        • Giannattasio C.
        • Mancia G.
        • Ferrari A.U.
        Heart rate-dependent stiffening of large arteries in intact and sympathectomised rats.
        Hypertension. 1999; 34: 598-602
        • Sa Cunha R.
        • Pannier B.
        • Benestos A.
        • et al.
        Association between high heart rate and high arterial rigidity in normotensive and hypertensive subjects.
        J Hypertens. 1997; 15: 1423-1430
        • Benetos A.
        • Adamopoulos C.
        • Bureau J.M.
        • et al.
        Determinants of accelerated progression of arterial stiffness in normotensive subjects and in treated hypertensive subjects over a 6-year period.
        Circulation. 2002; 105: 1202-1207
        • Albaladejo P.
        • Asmar R.
        • Safar M.
        • Benetos A.
        Association between 24-hour ambulatory heart rate and arterial stiffness.
        J Hum Hypertens. 2000; 14: 137-141
        • Giannattasio C.
        • Vincenti A.
        • Failla M.
        • et al.
        Effects of heart rate changes on arterial distensibility in humans.
        Hypertension. 2003; 42: 253-256
        • Wilkinson I.B.
        • MacCallum H.
        • Flint L.
        • et al.
        The influence of heart rate on augmentation index and central arterial pressure in humans.
        J Physiol. 2000; 525: 263-270
        • Wilkinson I.B.
        • Mohammad N.H.
        • Tyrrell S.
        • et al.
        Heart rate dependency of pulse pressure amplification and arterial stiffness.
        Am J Hypertens. 2002; 15: 24-30
        • Papaioannou T.G.
        • Vlachopoulos C.V.
        • Alexopoulos N.A.
        • et al.
        The effect of heart rate on wave reflections may be determined by the level of aortic stiffness: clinical and technical implications.
        Am J Hypertens. 2008; 21: 334-340
        • Williams B.
        • Lacy P.S.
        • Thom S.M.
        • et al.
        Differential impact of blood pressure-lowering drugs on central aortic pressure and clinical outcomes: principal results of the conduit artery function evaluation (CAFE) study.
        Circulation. 2006; 113: 1213-1225
        • Kelly R.
        • Daley J.
        • Avolio A.
        • O’Rourke M.
        Arterial dilation and reduced wave reflection. Benefit of dilevalol in hypertension.
        Hypertension. 1989; 14: 14-21